Back to Search
Start Over
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
- Source :
-
Mediators of Inflammation . 3/24/2016, p1-11. 11p. - Publication Year :
- 2016
-
Abstract
- Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09629351
- Database :
- Academic Search Index
- Journal :
- Mediators of Inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 113954401
- Full Text :
- https://doi.org/10.1155/2016/3094642